Company Dynamic

The EU approval shows GMO crop policy remains cautious, but not completely closed.

The EU approval shows GMO crop policy remains cautious, but not completely closed.

Deméter is entering China by selling not just seaweed extracts, but a clearer anti-stress value story.

Novo’s FDA warning is a reminder that compliance pressure grows alongside commercial success.

The founders’ planned exit marks a generational shift for BioNTech and the mRNA story it helped define.

BASF’s new biomass-balance polyols show how sustainability is becoming a practical industrial upgrade.

Symrise has announced the creation of a new Care & Wellness division, marking a strategic move to better align its capabilities across beauty, nutrition, and health.

• Symrise
• Care & Wellness division

In mid-March 2026, major news emerged from Yulong Island in Yantai, Shandong: the 100,000 tpa methyl methacrylate (MMA) unit has successfully started up in one go and produced on-spec products.

• Yulong Petrochemical

Advent will not buy LANXESS’s 40.94% stake in Envalior in 2026, delaying the roughly €1.2 billion transaction. LANXESS says liquidity and debt repayment remain secure despite the postponement.

Lilly is investing US$3 billion in China while using safety warnings to squeeze gray-market tirzepatide substitutes.

Entering March 2026, driven by surging energy prices caused by geopolitical turbulence and the continued rise in the costs of major raw materials such as natural rubber and synthetic rubber, the global rubber and downstream tire industry chain has ... ...

• LANXESS
• Rubber
• Tire

Dow’s back-to-back hikes in polyether polyols and MDI expose the deeper fragility of Europe’s polyurethane chain.

China’s approval of Pfizer’s GLP-1 therapy Xianweiying for long-term weight management is more than another product authorization. It is a sign that the country’s obesity and metabolic-health market is entering a far more competitive phase.

At first glance, the seizure of insulin stocks worth more than Rs 20 lakh in Delhi looks like a routine enforcement action. Yet the case carries a broader warning for India’s pharmaceutical distribution chain.

Beiersdorf recorded solid, if moderate, growth in fiscal year 2025 against a backdrop of continued volatility in the global skin-care market.

• Beiersdorf

BASF’s 2025 story is structural: faster cost cuts, reshaping the portfolio, and stronger cash focus to outlast a weak cycle.

BASF’s plan to sell 4,400 employee homes aims to free capital for core operations, exposing a sharper labor backlash in a weak cycle.

BASF reported weaker results for 2025 as challenging global market conditions weighed on performance.

• BASF

Merck plans to cut ~150 jobs at its US Gardasil plant as global HPV vaccine sales drop, reflecting shifting demand and production strategy.

South Korea–headquartered COSMAX has signed a share purchase agreement to acquire a 51% stake in Italian cosmetics ODM company Keminova, marking the establishment of its first manufacturing base in Europe.

• COSMAX
• Keminova